A small early‑phase study of a CRISPR‑based gene editing therapy significantly reduced LDL cholesterol and triglycerides in patients with heart disease, according to published data and AHA presentations. The treatment—delivered as a one‑time in vivo edit—produced dramatic lipid lowering in a 15‑patient cohort and was hailed as proof‑of‑concept for one‑and‑done cardiovascular interventions. Researchers and outside experts stressed the results are preliminary and flagged observed liver toxicities across similar programs as an area requiring close monitoring and mechanistic study. The trial’s small size and short follow‑up limit conclusions about long‑term safety and durability. The data nevertheless underscore the accelerating push to bring gene editing into mainstream cardiometabolic care and the trade‑offs companies face between transformative efficacy and novel safety profiles.